IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES NOVARTIS SUBSIDIARY LISTING
SWITZERLAND
CIBA VI SION
Full Name: Ciba Vi sion AG
Street Ad dress: Hardhofstrasse 15, CH-8424
Embrach
Tel: +41 1 866 41 00
Fax: +41 1 866 42 00
Home Page: www.cibavision.ch
De scrip tion: Re searcher, de vel oper, man u fac -
turer, for mu la tor, packager/as sem bler, im porter,
ex porter, dis trib u tor, pro moter, sales/detailer.
Man u fac tures for other com pa nies. Prod uct
ranges in clude: phar ma ceu ti cal prod ucts
(branded, pre scrip tion, non-pre scrip tion), hos pi -
tal pharmaceuticals, di ag nos tic prod ucts, oph -
thal mic prod ucts. Es tab lished 1964. 267
pharmaceutical employees in 2005.
Rep re sen ta tives/De tail ers (Pharm, Num -
ber): 1-10 (2005)
Con tacts (Pharm): Chair man: Luzi von Bid der;
Com mer cial Op er a tions: Julian Trimmimg; Man u -
fac ture: Fritz Glaser; Re search & De vel op ment:
An thony Ellery
Sub sid iary of: Novartis, Swit zer land (100%)
NOVARTIS
Full Name: Novartis In ter na tional AG
Postal Ad dress: Postfach, CH-4002 Basel
Street Ad dress: Fo rum 1, Novartis Cam pus,
CH-4056 Basel
Tel: +41 61 324 11 11
Fax: +41 61 324 80 01
Home Page: www.novartis.ch
De scrip tion: Es tab lished 1996. Di vi sions in -
clude: Healthcare; Nu tri tion; Ag ri busi ness.
Con tacts (Pharm): Chair man: Dan iel Vasella,
Ulrich Lehner, Hans-Joerg Rudloff; Com mer cial
Op er a tions: Thomas Wellauer, Ann Bailey; Mar ket
Re search: Paul Herrling; Gen eral Con tact:
Thomas Werlen
Par ent of: Novartis, Ar gen tina (100%); Sandoz,
Ar gen tina (100%); Novartis, Aus tra lia (100%);
Novartis Con sumer Health, Aus tra lia (100%);
Sandoz, Aus tra lia (100%); Novartis, Aus tria
(100%); Sandoz, Aus tria (100%); Novartis, Ban -
gla desh (60%); Ciba Vi sion, Bel gium (100%);
Novartis, Bel gium (100%); Novartis Con sumer
Health, Bel gium (100%); Sandoz, Bel gium
(100%); Novartis, Brazil (100%); Sandoz, Brazil
(100%); Ciba Vi sion, Can ada (100%); Novartis,
Can ada (100%); Sandoz, Can ada (100%);
Novartis, Chile (100%); Novartis, China (100%);
Novartis, Co lom bia (100%); Lek, Croatia
(100%); Novartis, Czech Re pub lic (100%);
Sandoz, Czech Re pub lic (100%); Novartis, Den -
mark (100%); Sandoz, Den mark (100%);
Novartis, Ec ua dor (100%); Novartis, Egypt
(99%); Novartis Con sumer Health, Egypt (96%);
Novartis, Fin land (100%); Ciba Vi sion, France
(100%); Novartis, France (100%); Novartis Con -
sumer Health, France (100%); Sandoz, France
(100%); 1A Pharma, Ger many (100%); Ciba Vi -
sion, Ger many (100%); Hexal, Ger many
(100%); Novartis, Ger many (100%); Novartis
Con sumer Health, Ger many (100%); Salutas,
Ger many; Sandoz, Ger many (100%); Sandoz
Pharma, Ger many (100%); Novartis, Greece
(100%); Novartis, Hong Kong (100%); Novartis,
Hun gary (100%); Sandoz, Hun gary (100%);
Novartis, In dia (51%); Sandoz, In dia (100%);
Ciba Vi sion, In do ne sia (100%); Novartis, In do ne -
sia (100%); Novartis, Ire land (100%); Ciba Vi -
sion, It aly (100%); Novartis, It aly (100%);
Novartis Con sumer Health, It aly (100%);
Sandoz, It aly (100%); Ciba Vi sion, Ja pan
(100%); Novartis, Ja pan (100%); Novartis, Lith -
u a nia; Novartis, Ma lay sia (100%); Novartis, Mex -
ico (100%); Novartis, Mo rocco (100%); Novartis,
Neth er lands (100%); Novartis Con sumer Health,
Neth er lands (100%); Sandoz, Neth er lands
(100%); Novartis, New Zea land (100%);
Novartis, Nor way (100%); Novartis, Pa ki stan
(98%); Novartis, Pan ama (100%); Novartis, Phil -
ip pines (100%); Lek, Po land (100%); Novartis,
Po land (100%); Novartis, Por tu gal (100%);
Novartis Con sumer Health, Por tu gal (100%);
Ciba Vi sion, Puerto Rico (100%); Ex Lax, Puerto
Rico (100%); Lek, Rus sia (100%); Novartis, Rus -
sia (100%); Novartis Con sumer Health, Rus sia
(100%); Ciba Vi sion, Sin ga pore (100%); Novartis
ITD, Sin ga pore (100%); Lek, Slovenia (100%);
Novartis, South Af rica (100%); Sandoz, South Af -
rica (100%); Novartis, South Ko rea (99%); Ciba
Vi sion, Spain (100%); Novartis, Spain (100%);
Novartis Con sumer Health, Spain (100%);
Sandoz, Spain (100%); Ciba Vi sion, Swe den
(100%); Novartis, Swe den (100%); Ciba Vi sion,
Swit zer land (100%); Novartis Con sumer Health,
Swit zer land (100%); Novartis Hold ing, Swit zer -
land (100%); Novartis Pharmaceuticals, Swit zer -
land (100%); Roche, Swit zer land (33.2%);
Sandoz, Swit zer land (100%); Speedel, Swit zer -
land; Novartis, Tai wan (100%); Novartis, Thai -
land (100%); Novartis, Tur key (100%); Sandoz,
© 2009 IMS Health In cor po rated or its af fil i ates Page 212